Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis

Surrey, Eric S.; Silverberg, Kaylen M.; Surrey, M.; Schoolcraft, William B.

doi:10.1016/s0015-0282(02)03373-3

Cited by 204 publications

(145 citation statements)

References 27 publications

Supporting

Mentioning

129

Contrasting

Unclassified

Order By: Relevance

“…Additional treatment with a gonadotropin-releasing hormone (GnRH) agonist (GnRHa) before IVF-ET (ultralong GnRHa therapy) improved the outcome of IVF-ET in endometriosis patients, as shown by increased numbers of retrieved oocytes and transferred embryos, and higher implantation and pregnancy rates [23][24][25]. However, the mechanism of ultralong GnRHa therapy is unclear.…”

Section: Introductionmentioning

confidence: 99%

A pilot study to search possible mechanisms of ultralong gonadotropin-releasing hormone agonist therapy in IVF-ET patients with endometriosis

Tamura

Takasaki

Nakamura

et al. 2014

Journal of Ovarian Research

View full text Add to dashboard Cite

Background: Additional treatment with a gonadotropin-releasing hormone (GnRH) agonist (GnRHa) before IVF-ET (ultralong GnRHa therapy) has been reported to improve the outcome of IVF-ET in endometriosis patients. However, the mechanism of ultralong GnRHa therapy is unclear. It is suggested that inflammatory cytokines and oxidative stress contribute to infertility in endometriosis patients. Therefore, in order to search a possible mechanism of ultralong GnRHa therapy, we investigated the effect of ultralong GnRHa therapy on intrafollicular concentrations of tumor necrosis factor alpha (TNFα), oxidative stress markers, and antioxidants in patients with endometriosis. Methods: Twenty-three infertile women with Stage III or IV endometriosis were recruited for this study. Eleven patients received three courses of GnRHa (1.8 mg s.c. every 28 days), followed by a standard controlled ovarian hyperstimulation (COH) for IVF-ET (ultralong group). The other 12 patients received a standard COH with mid-luteal phase GnRHa down-regulation (control group). The numbers of matured follicles and retrieved oocytes, fertilization rates, implantation rates, clinical pregnancy rate, and intrafollicular concentrations of TNFα, 8-hydroxy-2'-deoxyguanosine (8-OHdG) and hexanoyl-lysine adduct (HEL) as oxidative stress markers, and melatonin and Cu,Zu-superoxide dismutase (Cu,Zn-SOD) as antioxidants were compared between the two groups.

show abstract

Section: Introductionmentioning

confidence: 99%

A pilot study to search possible mechanisms of ultralong gonadotropin-releasing hormone agonist therapy in IVF-ET patients with endometriosis

Tamura

Takasaki

Nakamura

et al. 2014

Journal of Ovarian Research

View full text Add to dashboard Cite

show abstract

“…Therefore, we used half doses of the depot form of GnRH agonist to suppress the ovary. Furthermore, the ultra-long protocol, which includes 3 months of depot GnRH agonist injections to suppress the pituitary and endometriosis, seems to be the best choice in women with endometriosis undergoing IVF/ICSI cycles (12)(13)(14). One randomized study that compared depot forms of a GnRH agonist and antagonist reported similar IVF/ICSI outcomes (15).…”

Section: Discussionmentioning

confidence: 99%

A novel approach using a minimal number of injections during the IVF/ICSI cycle: Luteal half-dose depot GnRH agonist following corifollitropin alfa versus the corifollitropin alfa with a GnRH-antagonist cycle

Haydardedeoğlu

Kılıçdağ

2016

J Turkish German Gynecol Assoc

View full text Add to dashboard Cite

Results:The mean ages of the two groups were similar (32.77±5.55 vs. 34.2±4.51 years ["for the long-and antagonist-protocol groups, respectively"]). The total number of retrieved oocytes, the fertilization rate, and the number of transferred embryos were similar between the two groups. The only significant difference between the two protocols was the number of injections during the controlled ovarian stimulation (COH) cycle, which included the depot-agonist injection in the long-protocol group (4.46±1.64 vs. 5.71±2.51, p=0.006). The clinical pregnancy and implantation rates were similar in the two protocols (16/45 [35.6%] vs. 16/49 [32.7%] for the intention to treat and 32.5±6.82% vs. 36.25±8.58%, respectively). Conclusion:Our results show that ART cycles could be performed with fewer injections using corifollitropin alfa and a half-dose of depot GnRH agonist. (J Turk Ger Gynecol Assoc 2016; 17: 155-8) Keywords: Corifollitropin alfa, IVF/ICSI outcomes, depot GnRH agonist, GnRH antagonist Received: 18 March, 2016 Accepted: 27 June, 2016 A novel approach using a minimal number of injections during the IVF/ICSI cycle: Luteal half-dose depot GnRH agonist following corifollitropin alfa versus the corifollitropin alfa with a GnRH-antagonist cycle

show abstract

“…It is interesting to note that Thomas et al [10] have reported that the incidence of positive luminal epithelial staining of endometrial αvβ 3 vitronectin was significantly more common in women who conceived from IVF (P=0.027). Evidence suggesting that the use of GnRH agonists may play a role in restoration of expression of this integrin subtype and that pre-IVF cycle treatment of endometriosis patients with this agent enhances cycle outcome may be linked [12,14,15]. The fact that Group B patients who were αvβ 3 integrin negative and underwent prolonged GnRHa therapy had similar IVF cycle outcomes as those Group A patients who were αvβ 3 integrin positive and did not receive the agonist is encouraging but in no way definitive.…”

Section: Discussionmentioning

confidence: 99%

“…This may represent an explanation for the improved pregnancy rates which have been reported in endometriosis patients administered a prolonged course of GnRHa prior to in vitro fertilization [14,15].…”

mentioning

confidence: 90%

The incidence of aberrant endometrial αvβ3 vitronectin expression in a high risk infertility population: could prolonged GnRH agonist therapy play a role?

Surrey

Minjarez

Schoolcraft

2007

J Assist Reprod Genet

Self Cite

View full text Add to dashboard Cite

Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis

Cited by 204 publications

References 27 publications

A pilot study to search possible mechanisms of ultralong gonadotropin-releasing hormone agonist therapy in IVF-ET patients with endometriosis

A pilot study to search possible mechanisms of ultralong gonadotropin-releasing hormone agonist therapy in IVF-ET patients with endometriosis

A novel approach using a minimal number of injections during the IVF/ICSI cycle: Luteal half-dose depot GnRH agonist following corifollitropin alfa versus the corifollitropin alfa with a GnRH-antagonist cycle

The incidence of aberrant endometrial αvβ3 vitronectin expression in a high risk infertility population: could prolonged GnRH agonist therapy play a role?

Contact Info

Product

Resources

About